Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05433597 | A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC | not yet recruiting | Phase 2 / Phase 3 | 172 | Sun Yat-sen UniversityOTHER | 0 | Jun 27, 2022 | clinicaltrials |
| NCT04437329 | Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 352 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | May 10, 2022 |
| clinicaltrials |
| NCT05342792 | Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma | recruiting | Phase 3 | 556 | Sun Yat-sen UniversityOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05044117 | Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) | recruiting | Phase 3 | 220 | Sun Yat-sen UniversityOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT05062005 | ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 447 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT04376866 | Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 204 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT04890522 | An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC | not yet recruiting | Phase 2 / Phase 3 | 622 | Sun Yat-sen UniversityOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT04778956 | Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 218 | Sun Yat-sen UniversityOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT04215510 | Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT | not yet recruiting | Phase 3 | 286 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04448522 | Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma | recruiting | Phase 3 | 508 | Sun Yat-sen UniversityOTHER | 2 | Sep 28, 2020 | clinicaltrials |
| NCT04453813 | Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 226 | Sun Yat-sen UniversityOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT04136886 | Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma(IMRT) | recruiting | Phase 3 | 346 | Sun Yat-sen UniversityOTHER | 1 | Oct 23, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Jun 27, 2022source: clinicaltrials